

Jeffrey A Meyerhardt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2931400/publications.pdf>

Version: 2024-02-01

147
papers

15,246
citations

34493

54
h-index

20625

120
g-index

147
all docs

147
docs citations

147
times ranked

19153
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic Therapy for Colorectal Cancer. <i>New England Journal of Medicine</i> , 2005, 352, 476-487.	13.9	1,034
2	Physical Activity and Survival After Colorectal Cancer Diagnosis. <i>Journal of Clinical Oncology</i> , 2006, 24, 3527-3534.	0.8	762
3	Aspirin Use, Tumor <i>PIK3CA</i> Mutation, and Colorectal-Cancer Survival. <i>New England Journal of Medicine</i> , 2012, 367, 1596-1606.	13.9	752
4	CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. <i>Gut</i> , 2009, 58, 90-96.	6.1	682
5	Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. <i>Cell Reports</i> , 2016, 15, 857-865.	2.9	671
6	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2392.	3.8	670
7	Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803. <i>Journal of Clinical Oncology</i> , 2006, 24, 3535-3541.	0.8	664
8	Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. <i>Journal of Pathology</i> , 2010, 222, 350-366.	2.1	424
9	Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 914.	3.8	411
10	Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1086-1095.	0.8	383
11	Association of Dietary Patterns With Cancer Recurrence and Survival in Patients With Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 754.	3.8	369
12	Impact of Diabetes Mellitus on Outcomes in Patients With Colon Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 433-440.	0.8	368
13	Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator Phenotype. <i>Clinical Cancer Research</i> , 2009, 15, 6412-6420.	3.2	350
14	Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. <i>Journal of Clinical Oncology</i> , 2013, 31, 4465-4470.	0.8	313
15	Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2017, 3, e172319.	3.4	294
16	Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma. <i>Oncologist</i> , 2014, 19, 637-638.	1.9	292
17	Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. <i>Cancer</i> , 2003, 98, 484-495.	2.0	285
18	Explaining the Obesity Paradox: The Association between Body Composition and Colorectal Cancer Survival (C-SCANS Study). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1008-1015.	1.1	251

#	ARTICLE	IF	CITATIONS
19	The Role of Obesity in Cancer Survival and Recurrence. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1244-1259.	1.1	248
20	Impact of Body Mass Index on Outcomes and Treatment-Related Toxicity in Patients With Stage II and III Rectal Cancer: Findings From Intergroup Trial 0114. <i>Journal of Clinical Oncology</i> , 2004, 22, 648-657.	0.8	247
21	Impact of Body Mass Index and Weight Change After Treatment on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From Cancer and Leukemia Group B 89803. <i>Journal of Clinical Oncology</i> , 2008, 26, 4109-4115.	0.8	245
22	Association of Dietary Patterns With Risk of Colorectal Cancer Subtypes Classified by <i>Fusobacterium nucleatum</i> in Tumor Tissue. <i>JAMA Oncology</i> , 2017, 3, 921.	3.4	243
23	American Cancer Society nutrition and physical activity guideline for cancer survivors. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 230-262.	157.7	228
24	Aspirin Dose and Duration of Use and Risk of Colorectal Cancer in Men. <i>Gastroenterology</i> , 2008, 134, 21-28.	0.6	224
25	Physical Activity and Male Colorectal Cancer Survival. <i>Archives of Internal Medicine</i> , 2009, 169, 2102.	4.3	223
26	Insulin, the Insulin-Like Growth Factor Axis, and Mortality in Patients With Nonmetastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 176-185.	0.8	208
27	Role of Physical Activity and Diet After Colorectal Cancer Diagnosis. <i>Journal of Clinical Oncology</i> , 2015, 33, 1825-1834.	0.8	170
28	Dietary Glycemic Load and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings From CALGB 89803. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1702-1711.	3.0	163
29	Association between physical activity and mortality in colorectal cancer: A meta-analysis of prospective cohort studies. <i>International Journal of Cancer</i> , 2013, 133, 1905-1913.	2.3	160
30	Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis. <i>JAMA Oncology</i> , 2018, 4, 783.	3.4	147
31	Analysis of Body Mass Index and Mortality in Patients With Colorectal Cancer Using Causal Diagrams. <i>JAMA Oncology</i> , 2016, 2, 1137.	3.4	126
32	Development and Validation of the PREMM ₅ Model for Comprehensive Risk Assessment of Lynch Syndrome. <i>Journal of Clinical Oncology</i> , 2017, 35, 2165-2172.	0.8	126
33	Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. <i>Molecular Cancer</i> , 2014, 13, 135.	7.9	121
34	Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, 345.	3.0	115
35	Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 3671-3677.	0.8	112
36	Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	0.8	110

#	ARTICLE	IF	CITATIONS
37	Association of Hospital Procedure Volume and Outcomes in Patients with Colon Cancer at High Risk for Recurrence. <i>Annals of Internal Medicine</i> , 2003, 139, 649.	2.0	107
38	Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. <i>Hepatology</i> , 2018, 67, 1797-1806.	3.6	100
39	The Prognostic Role of Macrophage Polarization in the Colorectal Cancer Microenvironment. <i>Cancer Immunology Research</i> , 2021, 9, 8-19.	1.6	95
40	Muscle radiodensity and mortality in patients with colorectal cancer. <i>Cancer</i> , 2018, 124, 3008-3015.	2.0	92
41	Association of Low Muscle Mass and Low Muscle Radiodensity With Morbidity and Mortality for Colon Cancer Surgery. <i>JAMA Surgery</i> , 2020, 155, 942.	2.2	91
42	Association between Body Mass Index and Prognosis of Colorectal Cancer: A Meta-Analysis of Prospective Cohort Studies. <i>PLoS ONE</i> , 2015, 10, e0120706.	1.1	85
43	Effects of a 12-week home-based exercise program on the level of physical activity, insulin, and cytokines in colorectal cancer survivors: a pilot study. <i>Supportive Care in Cancer</i> , 2013, 21, 2537-2545.	1.0	82
44	The deterioration of muscle mass and radiodensity is prognostic of poor survival in stage III colorectal cancer: a population-based cohort study (<sc>Câ€SCANS</sc>). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 664-672.	2.9	80
45	Evaluation of automated computed tomography segmentation to assess body composition and mortality associations in cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 1258-1269.	2.9	79
46	Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The Câ€SCANS study. <i>Cancer</i> , 2017, 123, 4868-4877.	2.0	76
47	Post Diagnosis Diet Quality and Colorectal Cancer Survival in Women. <i>PLoS ONE</i> , 2014, 9, e115377.	1.1	74
48	Metabolic Dysfunction, Obesity, and Survival Among Patients With Early-Stage Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3664-3671.	0.8	69
49	Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance). <i>PLoS ONE</i> , 2014, 9, e99816.	1.1	65
50	Energetics in Colorectal and Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4066-4073.	0.8	61
51	Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 3598-3607.	0.8	60
52	Follow-up strategies after curative resection of colorectal cancer. <i>Seminars in Oncology</i> , 2003, 30, 349-360.	0.8	58
53	Tumor LINE-1 Methylation Level and Microsatellite Instability in Relation to Colorectal Cancer Prognosis. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	58
54	Impact of smoking on patients with stage III colon cancer. <i>Cancer</i> , 2010, 116, 957-966.	2.0	57

#	ARTICLE	IF	CITATIONS
55	Associations of pre-existing comorbidities with skeletal muscle mass and radiodensity in patients with non-metastatic colorectal cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 654-663.	2.9	55
56	Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers. <i>JAMA Network Open</i> , 2021, 4, e2139593.	2.8	55
57	Association of Weight Change after Colorectal Cancer Diagnosis and Outcomes in the Kaiser Permanente Northern California Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 30-37.	1.1	53
58	Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741. <i>Clinical Cancer Research</i> , 2008, 14, 8263-8269.	3.2	52
59	Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of Clinical Oncology</i> , 2019, 37, 2620-2631.	0.8	51
60	Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>Journal of Clinical Oncology</i> , 2018, 36, 1112-1120.	0.8	50
61	Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2012, 7, e38231.	1.1	48
62	Analysis of Survival Among Adults With Early-Onset Colorectal Cancer in the National Cancer Database. <i>JAMA Network Open</i> , 2021, 4, e2112539.	2.8	48
63	Obesity and Energy Balance in GI Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 4217-4224.	0.8	47
64	The association of medical and demographic characteristics with sarcopenia and low muscle radiodensity in patients with nonmetastatic colorectal cancer. <i>American Journal of Clinical Nutrition</i> , 2019, 109, 615-625.	2.2	45
65	Association Between Plasma Levels of Macrophage Inhibitory Cytokine-1 Before Diagnosis of Colorectal Cancer and Mortality. <i>Gastroenterology</i> , 2015, 149, 614-622.	0.6	44
66	Diet and Lifestyle in Survivors of Colorectal Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 1-27.	0.9	43
67	An exercise oncology clinical pathway: Screening and referral for personalized interventions. <i>Cancer</i> , 2020, 126, 2750-2758.	2.0	43
68	Effect of home-based exercise intervention on fasting insulin and Adipocytokines in colorectal cancer survivors: a randomized controlled trial. <i>Metabolism: Clinical and Experimental</i> , 2017, 76, 23-31.	1.5	43
69	The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1453-1459.	3.0	39
70	Moving through cancer: Setting the agenda to make exercise standard in oncology practice. <i>Cancer</i> , 2021, 127, 476-484.	2.0	38
71	The Association of Abdominal Adiposity With Mortality in Patients With Stage I-III Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2020, 112, 377-383.	3.0	33
72	Physical activity compared to adiposity and risk of liver-related mortality: Results from two prospective, nationwide cohorts. <i>Journal of Hepatology</i> , 2020, 72, 1062-1069.	1.8	32

#	ARTICLE	IF	CITATIONS
73	Impact of Physical Activity After Cancer Diagnosis on Survival in Patients With Recurrent Colon Cancer: Findings From CALGB 89803/Alliance. <i>Clinical Colorectal Cancer</i> , 2013, 12, 233-238.	1.0	31
74	Soluble tumour necrosis factor receptor type II and survival in colorectal cancer. <i>British Journal of Cancer</i> , 2016, 114, 995-1002.	2.9	31
75	Beyond Standard Adjuvant Therapy for Colon Cancer: Role of Nonstandard Interventions. <i>Seminars in Oncology</i> , 2011, 38, 533-541.	0.8	30
76	Smoking and Risk of Colorectal Cancer Sub-Classified by Tumor-Infiltrating T Cells. <i>Journal of the National Cancer Institute</i> , 2019, 111, 42-51.	3.0	30
77	Systemic chemotherapy and survival in patients with metastatic low-grade appendiceal mucinous adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2019, 120, 446-451.	0.8	28
78	A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classification. <i>Cancer Treatment Reviews</i> , 2022, 103, 102325.	3.4	26
79	Timing of Aspirin Use in Colorectal Cancer Chemoprevention: A Prospective Cohort Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 841-851.	3.0	24
80	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of the National Cancer Institute</i> , 2022, 114, 427-435.	3.0	24
81	Assessment of a Dietary Questionnaire in Cancer Patients Receiving Cytotoxic Chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 8453-8460.	0.8	23
82	Prediagnostic Plasma Adiponectin and Survival among Patients with Colorectal Cancer. <i>Cancer Prevention Research</i> , 2015, 8, 1138-1145.	0.7	23
83	Spatial Organization and Prognostic Significance of NK and NKT-like Cells via Multimarker Analysis of the Colorectal Cancer Microenvironment. <i>Cancer Immunology Research</i> , 2022, 10, 215-227.	1.6	23
84	Non-alcoholic fatty liver disease and colorectal cancer survival. <i>Cancer Causes and Control</i> , 2019, 30, 165-168.	0.8	22
85	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz078.	1.4	22
86	Psychological symptoms and subsequent healthy lifestyle after a colorectal cancer diagnosis. <i>Health Psychology</i> , 2018, 37, 207-217.	1.3	22
87	An integrated analysis of lymphocytic reaction, tumour molecular characteristics and patient survival in colorectal cancer. <i>British Journal of Cancer</i> , 2020, 122, 1367-1377.	2.9	21
88	Tumor Long Interspersed Nucleotide Element-1 (LINE-1) Hypomethylation in Relation to Age of Colorectal Cancer Diagnosis and Prognosis. <i>Cancers</i> , 2021, 13, 2016.	1.7	21
89	Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). <i>Journal of Clinical Oncology</i> , 2022, 40, 740-751.	0.8	20
90	Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). <i>Journal of the National Cancer Institute</i> , 2019, 111, 170-179.	3.0	19

#	ARTICLE	IF	CITATIONS
91	Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1402-1410.	1.1	18
92	Comparison of Dietary and Lifestyle Habits Among Stage III and Metastatic Colorectal Cancer Patients: Findings from CALGB 89803 and CALGB 80405. <i>Clinical Colorectal Cancer</i> , 2013, 12, 95-102.	1.0	17
93	Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. <i>Cancer Prevention Research</i> , 2020, 13, 1055-1062.	0.7	17
94	Smoking and Incidence of Colorectal Cancer Subclassified by Tumor-Associated Macrophage Infiltrates. <i>Journal of the National Cancer Institute</i> , 2022, 114, 68-77.	3.0	17
95	Post-diagnosis dietary insulinemic potential and survival outcomes among colorectal cancer patients. <i>BMC Cancer</i> , 2020, 20, 817.	1.1	16
96	Sugar-sweetened beverage and sugar consumption and colorectal cancer incidence and mortality according to anatomic subsite. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 1481-1489.	2.2	16
97	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , 2020, 130, 63-71.	1.3	15
98	Chemotherapy options for gastric cancer. <i>Seminars in Radiation Oncology</i> , 2002, 12, 176-186.	1.0	14
99	5-Fluorouracil induced liver toxicity in patients with colorectal cancer: role of computed tomography texture analysis as a potential biomarker. <i>Abdominal Radiology</i> , 2019, 44, 3099-3106.	1.0	14
100	Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer Survivors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz096.	1.4	14
101	Yoga for chronic chemotherapy-induced peripheral neuropathy pain: a pilot, randomized controlled trial. <i>Journal of Cancer Survivorship</i> , 2022, 16, 882-891.	1.5	14
102	Recruitment strategies and design considerations in a trial of resistance training to prevent dose-limiting toxicities in colon cancer patients undergoing chemotherapy. <i>Contemporary Clinical Trials</i> , 2021, 101, 106242.	0.8	13
103	Long-Term Statin Use, Total Cholesterol Level, and Risk of Colorectal Cancer: A Prospective Cohort Study. <i>American Journal of Gastroenterology</i> , 2022, 117, 158-166.	0.2	13
104	Risk Factors and Incidence of Colorectal Cancer According to Major Molecular Subtypes. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa089.	1.4	11
105	Dairy intake during adolescence and risk of colorectal adenoma later in life. <i>British Journal of Cancer</i> , 2021, 124, 1160-1168.	2.9	11
106	Plasma metabolomic profiles for colorectal cancer precursors in women. <i>European Journal of Epidemiology</i> , 2022, 37, 413-422.	2.5	11
107	Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2779-2788.	3.2	11
108	Efficacy of Cetuximab After Treatment with Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Based Chemotherapy in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2006, 6, 59-65.	1.0	10

#	ARTICLE	IF	CITATIONS
109	Physical Activity and Colorectal Cancer Prognosis According to Tumor-Infiltrating T Cells. JNCI Cancer Spectrum, 2018, 2, pky058.	1.4	10
110	Impact of Diet and Exercise on Colorectal Cancer. Hematology/Oncology Clinics of North America, 2022, 36, 471-489.	0.9	10
111	Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer. Clinical Cancer Research, 2016, 22, 1489-1498.	3.2	9
112	Unrestrained eating behavior and risk of digestive system cancers: a prospective cohort study. American Journal of Clinical Nutrition, 2021, 114, 1612-1624.	2.2	9
113	Sugar-sweetened beverage, artificially sweetened beverage and sugar intake and colorectal cancer survival. British Journal of Cancer, 2021, 125, 1016-1024.	2.9	9
114	Abdominal adipose tissue radiodensity is associated with survival after colorectal cancer. American Journal of Clinical Nutrition, 2021, 114, 1917-1924.	2.2	9
115	Desmoplastic Reaction, Immune Cell Response, and Prognosis in Colorectal Cancer. Frontiers in Immunology, 2022, 13, 840198.	2.2	9
116	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectrum, 2020, 4, pkaa024.	1.4	8
117	Smoking Status at Diagnosis and Colorectal Cancer Prognosis According to Tumor Lymphocytic Reaction. JNCI Cancer Spectrum, 2020, 4, pkaa040.	1.4	8
118	A Modified Tumor-Node-Metastasis Classification for Primary Operable Colorectal Cancer. JNCI Cancer Spectrum, 2021, 5, pkaa093.	1.4	8
119	Adjuvant therapy in gastric cancer: can we prevent recurrences?. Oncology, 2003, 17, 714-21, 728; discussion 728-9, 732-3.	0.4	8
120	Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). Endocrine-Related Cancer, 2022, 29, 335-344.	1.6	8
121	Postdiagnostic dairy products intake and colorectal cancer survival in US males and females. American Journal of Clinical Nutrition, 2021, 113, 1636-1646.	2.2	7
122	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectrum, 2021, 5, pkaa074.	1.4	6
123	Unrestrained eating behavior and risk of mortality: A prospective cohort study. Clinical Nutrition, 2021, 40, 5419-5429.	2.3	5
124	Reported behavior of eating anything at anytime and risk of colorectal cancer in women. International Journal of Cancer, 2012, 130, 1395-1400.	2.3	4
125	Cardiopulmonary fitness, adiponectin, chemerin associated fasting insulin level in colorectal cancer patients. Supportive Care in Cancer, 2016, 24, 2927-35.	1.0	3
126	Coffee Intake and Colorectal Cancer Incidence According to T-Cell Response. JNCI Cancer Spectrum, 2020, 4, pkaa068.	1.4	3

#	ARTICLE	IF	CITATIONS
127	Coffee Intake of Colorectal Cancer Patients and Prognosis According to Histopathologic Lymphocytic Reaction and T-Cell Infiltrates. <i>Mayo Clinic Proceedings</i> , 2022, 97, 124-133.	1.4	3
128	Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. <i>Journal of Geriatric Oncology</i> , 2022, 13, 469-479.	0.5	3
129	Epidermal growth factor receptor inhibitors and colorectal cancer. <i>Oncology</i> , 2004, 18, 35-8.	0.4	3
130	Can we change the past for colorectal cancer patients and how do we move forward?. <i>Cancer</i> , 2014, 120, 1450-1452.	2.0	2
131	Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 325-325.	0.8	2
132	Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. <i>Oncologist</i> , 2022, 27, 292-298.	1.9	2
133	Adjuvant therapy for stage II and III colon cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 772-4.	0.3	2
134	Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202.. <i>Journal of Clinical Oncology</i> , 2021, 39, 361-361.	0.8	1
135	Irinotecan, cetuximab, and bevacizumab (CBI) versus irinotecan, cetuximab, and placebo (CI) in irinotecan-refractory metastatic colorectal cancer (mCRC): Results from an ACCRU network randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 102-102.	0.8	1
136	Exercise after cancer diagnosis: time to get moving. <i>Oncology</i> , 2013, 27, 585-6, 588.	0.4	1
137	Perioperative chemotherapy for colorectal cancer liver metastases. <i>Oncology</i> , 2013, 27, 1088-90.	0.4	1
138	Serological testing for SARS-CoV-2 antibodies of employees shows low transmission working in a cancer center. <i>PLoS ONE</i> , 2022, 17, e0266791.	1.1	1
139	Stage III Colon Cancer: What Works, What Doesn't and Why, and What's Next. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 223-230.	1.8	0
140	Response. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju181-dju181.	3.0	0
141	Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3517-3517.	0.8	0
142	Influence of dietary insulin scores on survival in patients with metastatic colorectal cancer (mCRC): Findings from CALGB (Alliance) 80405.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3568-3568.	0.8	0
143	Dietary fat in relation to overall and progression-free survival among patients (pts) with advanced or metastatic colorectal cancer (CRC): Data from CALGB 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3588-3588.	0.8	0
144	Prognostic value of tumor deposits in stage III colon cancer patients, a post-hoc analysis of CALGB/SWOG 80702 phase III study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10-10.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative science from CALGB 80802 (Alliance).. Journal of Clinical Oncology, 2021, 39, 343-343.	0.8	0
146	Determining the optimal duration of adjuvant therapy in colon cancer. Clinical Advances in Hematology and Oncology, 2021, 19, 220-222.	0.3	0
147	Smoking and colorectal cancer survival in relation to tumor LINE-1 methylation levels: a prospective cohort study. , 2022, 2, .		0